Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG reports positive results from UK Varisolve trials

BTG : 13 October, 2006  (Company News)
BTG, the global technology commercialisation company, today announced that its wholly owned subsidiary, Provensis, reported findings from the independent physician-led trials of Varisolve, the new microfoam treatment for varicose veins. Two pilot studies were conducted in Aberdeen and Manchester and both demonstrated the treatment to be safe and effective.
The trials were conducted in two medical centres, South Manchester University and Aberdeen Royal Infirmary. Forty-one patients with moderate to severe varicose veins, who would normally be treateded with surgery, participated in the trials. Patients each received either one or two injection treatments within a one-week interval. All patients were able to return to work the same or following day. The treatment was well tolerated and no significant side effects were detected.

The overall success rate of the treatment was 81% and was comparable to the outcome from surgical treatment. Success was measured by ultra-sound examination showing elimination of abnormal retrograde blood flow into the veins and of closure of the varicose vein.

Varisolve is an outpatient treatment for varicose veins and is being developed by Provensis to provide an alternative to surgery. Over 150 million people in the US and Europe suffer from significant varicose veins. Four million new cases of varicose veins develop each year.

Professor Charles McCollum who led the work in Manchester said: 'I am very excited by the Varisolve treatment and believe that with the right personnel, equipment and training, people suffering from major varicose veins can be treated as outpatients with remarkably little discomfort. The results are at least as good as surgery without the scars or the painful recovery time.'

Ian Harvey, Chief Executive Officer of BTG and Chairman of Provensis, commented: 'We are very pleased with these results from this independent study. They have reconfirmed our expectations for Varisolve and have demonstrated the potential of the procedure as an outpatient alternative to surgery for the treatment of varicose veins.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo